Linical Americas Named Recipient of 2020 CRO Leadership Award
STUART, FL. June 10, 2020 -
Linical Americas, a market-leading, midsized, global contract research organization (CRO), has been named a winner of a 2020 CRO Leadership Award for Overall Compatibility servicing a combination of both large and small pharma and biotech clientele.
The 2020 CRO Leadership Awards, presented by Life Science Leader and Clinical Leader, are determined according to research conducted by Industry Standard Research (ISR). Over 60 contract research organizations were assessed on more than 20 performance metrics in ISR’s annual CRO Quality Benchmarking survey. Survey participants were recruited from pharma and biotech companies of all sizes based on companies with which they have worked in the past 18 months. This level of stringent qualification ensures that survey responses are based on actual involvement with CROs and clear experiential data.
"When talking to clinical operations executives, I'm told the CRO selection process can be one of their most stressful and time-consuming chores," says Ed Miseta, chief editor, Clinical Leader. "Anything we can do to help steer our readers to those partners that best meet their needs can significantly reduce the burden of their search. That is why we are once again proud to partner with Industry Standard Research to produce our annual CRO Leadership Awards. Linical Americas and the organizations being honored have proven themselves to be the top performers in Compatibility, Capabilities, Expertise, Quality, Reliability, and Phase IV. We applaud these companies for their hard work in meeting the needs and expectations of their pharma and biotech clients."
“The entire team at Linical is honored to have been named a recipient of the 2020 CRO Leadership Award for Overall Compatibility,” stated Vita Lanoce, CEO of Linical Americas. “We realize clients have to weigh many factors when choosing their clinical trial service providers, and we are proud that both small and large clients alike value their partnerships with us. Here at Linical, we believe in being accessible, adaptable, and solution oriented to help our clients, with a shared goal of bringing their promising therapies to market to improve the lives of patients.”
Linical is a public, midsized CRO headquartered in Japan with a significant presence across North America, Europe, and Asia-Pacific. Linical provides the full spectrum of drug development services from early stage to large-scale, multinational studies. The company’s areas of expertise include Phase I-IV oncology, vaccine, infectious disease, CNS and general medicine.